Gianluca Chiarappa
University of Trieste
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gianluca Chiarappa.
Materials | 2017
Nadia Halib; Francesca Perrone; Maja Cemazar; Barbara Dapas; Rossella Farra; Michela Abrami; Gianluca Chiarappa; Giancarlo Forte; Fabrizio Zanconati; Gabriele Pozzato; Luigi Murena; Nicola Fiotti; Romano Lapasin; Laura Cansolino; Gabriele Grassi; Mario Grassi
Because of its high biocompatibility, bio-degradability, low-cost and easy availability, cellulose finds application in disparate areas of research. Here we focus our attention on the most recent and attractive potential applications of cellulose in the biomedical field. We first describe the chemical/structural composition of cellulose fibers, the cellulose sources/features and cellulose chemical modifications employed to improve its properties. We then move to the description of cellulose potential applications in biomedicine. In this field, cellulose is most considered in recent research in the form of nano-sized particle, i.e., nanofiber cellulose (NFC) or cellulose nanocrystal (CNC). NFC is obtained from cellulose via chemical and mechanical methods. CNC can be obtained from macroscopic or microscopic forms of cellulose following strong acid hydrolysis. NFC and CNC are used for several reasons including the mechanical properties, the extended surface area and the low toxicity. Here we present some potential applications of nano-sized cellulose in the fields of wound healing, bone-cartilage regeneration, dental application and different human diseases including cancer. To witness the close proximity of nano-sized cellulose to the practical biomedical use, examples of recent clinical trials are also reported. Altogether, the described examples strongly support the enormous application potential of nano-sized cellulose in the biomedical field.
Expert Opinion on Drug Delivery | 2017
Lucia Scarabel; Francesca Perrone; Marica Garziera; Rossella Farra; Mario Grassi; Francesco Musiani; Concetta Russo Spena; Barbara Salis; Lucia De Stefano; Giuseppe Toffoli; Flavio Rizzolio; Federica Tonon; Michela Abrami; Gianluca Chiarappa; Gabriele Pozzato; Giancarlo Forte; Gabriele Grassi; Barbara Dapas
ABSTRACT Introduction: hepatocellular carcinoma (hcc) is the predominant form of primary liver cancer and the second leading cause of cancer-associated mortality worldwide. available therapies for hcc have limited efficacy due to often late diagnosis and the general resistance of hcc to anti-cancer agents; therefore, the development of novel therapeutics is urgently required. small-interfering rna (sirna) molecules are short, double-stranded rnas that specifically recognize and bind the mrna of a target gene to inhibit gene expression. despite the great therapeutic potential of sirnas towards many human tumors including hcc, their use is limited by suboptimal delivery. Areas covered: In this review, we outline the current data regarding the therapeutic potential of siRNAs in HCC and describe the development of effective siRNA delivery systems. We detail the key problems associated with siRNA delivery and discuss the possible solutions. Finally, we provide examples of the various siRNA delivery strategies that have been employed in animal models of HCC and in human patients enrolled in clinical trials. Expert opinion: Despite the existing difficulties in siRNA delivery for HCC, the increasing scientific attention and breakthrough studies in this field is facilitating the design of novel and efficient technical solutions that may soon find practical applications.
Current Drug Delivery | 2016
Gianluca Chiarappa; Mario Grassi; Michela Abrami; Roberto Abbiati; Anna Angela Barba; Anja Boisen; Valerio Brucato; Giulio Ghersi; Diego Caccavo; Sara Cascone; Nicola Elvassore; Monica Giomo; Stefano Guido; Gaetano Lamberti; Domenico Larobina; Davide Manca; Paolo Marizza; Gabriele Grassi
Modern Chemical Engineering was born around the end of the 19th century in Great Britain, Germany, and the USA, the most industrialized countries at that time. Milton C. Whitaker, in 1914, affirmed that the difference between Chemistry and Chemical Engineering lies in the capability of chemical engineers to transfer laboratory findings to the industrial level. Since then, Chemical Engineering underwent huge transformations determining the detachment from the original Chemistry nest. The beginning of the sixties of the 20th century saw the development of a new branch of Chemical Engineering baptized Biomedical Engineering by Peppas and Langer and that now we can name Biological Engineering. Interestingly, although Biological Engineering focused on completely different topics from Chemical Engineering ones, it resorted to the same theoretical tools such as, for instance, mass, energy and momentum balances. Thus, the birth of Biological Engineering may be considered as a Darwinian evolution of Chemical Engineering similar to that experienced by mammals which, returning to water, used legs and arms to swim. From 1960 on, Biological Engineering underwent a considerable evolution as witnessed by the great variety of topics covered such as hemodialysis, release of synthetic drugs, artificial organs and, more recently, delivery of small interfering RNAs (siRNA). This review, based on the activities developed in the frame of our PRIN 2010-11 (20109PLMH2) project, tries to recount origins and evolution of Chemical Engineering illustrating several examples of recent and successful applications in the biological field. This, in turn, may stimulate the discussion about the Chemical Engineering students curriculum studiorum update.
International Journal of Pharmaceutics | 2017
Anna Angela Barba; Sara Cascone; Diego Caccavo; Gaetano Lamberti; Gianluca Chiarappa; Michela Abrami; Gabriele Grassi; Mario Grassi; Stefano Guido; Valerio Brucato; Francesco Carfì Pavia; Giulio Ghersi; Vincenzo La Carrubba; Roberto Abbiati; Davide Manca
Archive | 2018
Gianluca Chiarappa; Michela Abrami; Rossella Farra; Barbara Dapas; Gabriele Grassi; Mario Grassi
Journal of Food Engineering | 2018
Gianluca Chiarappa; María Dolores De’Nobili; Ana M. Rojas; Michela Abrami; Romano Lapasin; Gabriele Grassi; José Augusto Ferreira; E. Gudiño; Paula de Oliveira; Mario Grassi
ADMET and DMPK | 2018
Michaela Abrami; Gianluca Chiarappa; Rossella Farra; Gabriele Grassi; Paolo Marizza; Mario Grassi
Natural Product Communications | 2017
Gianluca Chiarappa; Michela Abrami; Barbara Dapas; Rossella Farra; Fabio Trebez; Francesco Musiani; Gabriele Grassi; Mario Grassi
Crystal Growth & Design | 2017
Gianluca Chiarappa; Andrea Piccolo; Italo Colombo; Dritan Hasa; Dario Voinovich; Mariarosa Moneghini; Gabriele Grassi; Rossella Farra; Michela Abrami; Paola Posocco; Sabrina Pricl; Mario Grassi
6th IAPC Meeting | 2017
Michela Abrami; Gianluca Chiarappa; Rossella Farra; Gabriele Grassi; Paolo Marizza; Mario Grassi